<DOC>
	<DOCNO>NCT01263691</DOCNO>
	<brief_summary>The purpose Phase 1 clinical trial evaluate safety , tolerability , immunogenicity AV7909 anthrax vaccine healthy adult . In study , healthy male female subject 18 50 year age receive vaccination via intramuscular ( IM ) route Days 0 14 . Safety tolerability evaluate via laboratory test , physical examination , vital sign , adverse event ( AEs ) , concomitant medication , local systemic sign symptom reactogenicity .</brief_summary>
	<brief_title>Safety , Tolerability Immunogenicity Study AV7909 Anthrax Vaccine Healthy Adults</brief_title>
	<detailed_description>AV7909 new vaccine combination BioThrax ( also call anthrax vaccine , adsorb AVA ) , FDA-licensed vaccine , CPG 7909 . CPG 7909 synthetic short DNA sequence show effective vaccine adjuvant , one increase speed degree immune response Protective Antigen ( PA ) , major vaccine antigen . In current study , safety , tolerability , antibody response PA study four different combination AVA CPG 7909 , compare AVA saline placebo . All formulation AV7909 less AVA license AVA vaccine less CPG 7909 per dose formulation use first Phase I volunteer study CPG 7909 combine AVA .</detailed_description>
	<mesh_term>Anthrax</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Be 18 50 year age , inclusive , time enrollment . Be good health determine investigator medical history physical examination . If premenopausal female , must use acceptable method birth control . Have hematology chemistry parameter ( measure Screening ) within laboratory 's normal range . Have negative value follow test Screening : Hepatitis C antibody , antiHuman Immunodeficiency Virus ( AntiHIV1/2/O ) , antiHepatitis B Core Antigen ( AntiHBc ) . Be willing capable comply aspect protocol completion require visit . Have donate blood precede 8 week willing donate blood plasma within 56 day dose . Have adequate venous access repeat phlebotomy . Have read , understood sign informed consent form . Key A know anaphylactic response , severe systematic response , serious hypersensitivity reaction prior immunization . Prior immunization anthrax vaccine , recombinant Protective Antigen ( rPA ) vaccine , know exposure anthrax organism . Have previously serve military plan enlist military Screening Day 84 . Have participate anthrax therapeutic vaccine trial ( monoclonal antiprotective antigen ( PA ) anthrax immune globulin anthrax vaccine ) . Participation investigational clinical trial within 30 day precede Screening visit planning participate clinical trial require dose Day 194 visit . A history drug alcohol abuse within 12 month prior Screening , positive result urine drug screen amphetamine , barbiturate , benzodiazepine , cocaine , marijuana , methylenedioxymethamphetamine opiate , oxycodone , phencyclidine , propoxyphene , tricyclic antidepressant . Blood pressure great 145 millimeter mercury ( mmHg ) systolic 90 mmHg diastolic . Past history significant autoimmune disease rheumatoid arthritis , lupus erythematous , psoriasis , glomerulonephritis , autoimmune thyroiditis . A medical condition , opinion Principal Investigator ( PI ) , could adversely impact subject 's participation , safety , conduct study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>AVA</keyword>
	<keyword>AV7909</keyword>
	<keyword>Anthrax vaccine</keyword>
</DOC>